摘要
目的助力云南制药企业把握国家组织药品集中带量采购(简称带量采购)政策机遇进行结构转型,促进其创新、高质量发展。方法通过文件及文献梳理、知情访谈、实地调研、专家咨询等方式,了解云南制药企业的发展现状,以及参与带量采购企业中标情况,分析带量采购政策给云南制药企业带来的挑战与机遇,并有针对性地提出发展建议。结果云南制药企业的整体规模小,发展水平不高,配套体系不健全;产业发展滞后,知名企业、龙头企业少;研发创新能力和投入不足;人才匮乏,管理机制不健全;产业投资、企业融资等促转型发展政策落实不足。带量采购政策的常态化推进,优胜劣汰的趋势倒逼制药企业改革和创新,可提高云南制药企业的产业集中度,也可促进其研发创新,改变传统发展模式。结论云南制药企业亟需重视研发创新、畅通融资渠道、明晰人才需求、构筑良好的投标信用体系,提升产品质量和制药企业的综合竞争力,主动迎接挑战,把握带量采购政策带来的机遇。
ObjectiveTo help Yunnan pharmaceutical enterprises seize the opportunity from the national centralized drug-procurement(NCDP)policy to carry out the structural transformation,and to promote their innovative and high-quality development.MethodsThe development status of Yunnan pharmaceutical enterprises and the bid-winning status of enterprises through the NCDP policy were discussed by the literature material law,interview with informed consent,field research,expert consultation and other methods,the challenges and opportunities of Yunnan pharmaceutical enterprises from the NCDP policy were analyzed,and the development suggestions were put forward accordingly.ResultsThe overall scale of Yunnan pharmaceutical enterprises was small,the level of development was not high,the supporting system was not incomplete,the industrial development lagged behind,the number of well-known enterprises and leading enterprises was few,the innovation ability and investment of research and development(R&D)were insufficient,the talents were scarce,the management mechanism was incomplete,and the industrial investment,enterprise financing and other policies to promote the transformation and development were not fully implemented.The normalized promotion of NCDP policy and the trend of survival of the fittest drived the reform and innovation of pharmaceutical enterprises reversely,which could improve the industrial concentration of Yunnan pharmaceutical enterprises,promote their R&D and innovation,and change the traditional development mode.ConclusionYunnan pharmaceutical enterprises urgently need to pay attention to the R&D and innovation,open financing channels,define talent demand and establish a good bidding credit system.They also need to improve product quality and the comprehensive competitiveness,take the initiative to respond to challenges and seize the opportunities from the NCDP policy.
作者
胡若飞
李婵
邹佳
锁驰
赵雪娟
李璠
HU Ruofei;LI Chan;ZOU Jia;SUO Chi;ZHAO Xuejuan;LI Fan(School of Pharmacy,Kunming Medical University·Yunnan Key Laboratory of Pharmacology for Natural Products,Kunming,Yunnan,China 650500;Yunnan Drug Policy Research Center,Kunming,Yunnan,China 650500)
出处
《中国药业》
CAS
2023年第5期1-5,共5页
China Pharmaceuticals
基金
云南省医疗保障局委托项目[2020YNPP001]。
关键词
国家组织药品集中带量采购
云南省
制药企业
发展机遇
national centralized drug-procurement
Yunnan Province
pharmaceutical enterprise
development opportunity
